CDKAL1 (CDK5 Regulatory Subunit Associated Protein 1-like 1) is a human gene encoding a highly conserved tRNA modification enzyme critical for cellular protein synthesis. The CDKAL1 protein is a member of the Cdk5 regulatory subunit-associated protein family, though its primary function is not related to CDK5 regulation. Instead, CDKAL1 catalyzes the 2-thiolation of cytidine at position 34 (s²C34) in specific tRNAs, a modification essential for translation accuracy and efficiency[1].
Located at chromosome 5p13.3, the CDKAL1 gene encodes a 507-amino acid protein that belongs to the THiS family of tRNA modification enzymes. The enzyme requires a [4Fe-4S] iron-sulfur cluster for catalytic activity, linking its function to cellular iron metabolism. CDKAL1's role in tRNA modification has significant implications for protein synthesis fidelity, which is particularly important in metabolically active cells like neurons that require precise proteostasis.
Originally identified through genome-wide association studies (GWAS) as a significant risk locus for type 2 diabetes mellitus, CDKAL1 has since attracted attention in the neuroscience community due to emerging evidence linking tRNA modifications to neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and Amyotrophic Lateral Sclerosis (ALS) [2].
CDKAL1 catalyzes the addition of a sulfur atom to the 2-position of cytidine at position 34 in tRNA. This position is the "wobble" position of the anticodon, which plays a critical role in codon-anticodon pairing during translation[3].
The 2-thiolation modification (s²C) occurs primarily on tRNA species that recognize codons ending in G. These include:
The s²C modification enhances the binding affinity between the anticodon and codon, particularly for A-ended codons. This stabilization is critical for maintaining reading frame accuracy during translation.
CDKAL1 requires iron-sulfur cluster cofactors for catalytic activity. The enzyme uses a sulfur relay system involving:
This requirement connects CDKAL1 function to cellular iron homeostasis and oxidative stress responses. Conditions that disrupt iron-sulfur cluster assembly impair CDKAL1 activity, leading to downstream effects on translation fidelity.
CDKAL1 shows substrate specificity for specific tRNA species based on their anticodon sequences. The enzyme primarily modifies tRNAs with uridine at the first anticodon position (position 34) that recognize codons ending in purines (A or G).
The target tRNAs include those encoding lysine, glutamine, glutamate, and arginine. These amino acids are encoded by multiple codons, and the s²C modification improves decoding efficiency at specific codon families.
CDKAL1-mediated tRNA thiolation is essential for maintaining translation fidelity. Without s²C modification, the wobble interaction between tRNA and codon is weakened, leading to[4]:
The 2-thiolation modification increases the stability of the codon-anticodon pair by approximately 1 kcal/mol, sufficient to significantly improve decoding accuracy. In the absence of CDKAL1, mistranslation rates increase significantly, leading to proteostatic stress.
The s²C modification specifically prevents ribosome stalling at proline-rich sequences. Proline is unique among amino acids because its secondary amine backbone cannot form the typical hydrogen bonds that stabilize the peptide bond. This causes ribosomes to pause at polyproline sequences[5].
The s²C modification on tRNA^Arg(UCU) and other tRNAs facilitates the incorporation of proline by improving codon recognition and preventing ribosome stalling. CDKAL1 deficiency leads to ribosomal accumulation at polyproline sequences, reducing translation efficiency.
CDKAL1 is highly expressed in neurons, particularly at synapses, where local protein synthesis is essential for synaptic plasticity. The enzyme is required for synthesizing synaptic proteins that contain proline-rich domains, including[6]:
Synaptic dysfunction in CDKAL1-deficient neurons involves impaired synthesis of proteins critical for synaptic plasticity, learning, and memory.
CDKAL1 is expressed throughout the brain, with highest levels in the hippocampus, cortex, and cerebellum. In neurons, CDKAL1 localizes to both the soma and dendritic compartments, including dendritic spines.
Neuronal CDKAL1 expression is activity-dependent. Synaptic activity upregulates CDKAL1 levels, suggesting it responds to functional demands for protein synthesis. This regulation may be important for synaptic plasticity and memory consolidation.
While primarily a neuronal protein, CDKAL1 is also expressed in astrocytes and microglia. In these glial cells, CDKAL1 may support the high metabolic demands of glial function, including neurotransmitter recycling and immune modulation.
The most well-established disease association of CDKAL1 is with type 2 diabetes mellitus (T2DM). Multiple GWAS studies have identified variants in the CDKAL1 gene region as significant determinants of T2DM risk[2:1]. The mechanism involves impaired β-cell function:
In Alzheimer's disease, several tRNA modifications are altered, including s²C modification by CDKAL1. Studies show reduced CDKAL1 expression in AD brains[8], which may contribute to the translation deficits observed in AD neurons.
The loss of CDKAL1 function in AD may result from:
AD brains exhibit global translation deficits, including reduced ribosomal function and impaired protein synthesis. CDKAL1 deficiency contributes to these deficits through multiple mechanisms:
These translation deficits may contribute to synaptic dysfunction and neuronal death in AD. CDKAL1 may interact with amyloid-beta pathology through effects on protein quality control. Cells with CDKAL1 deficiency are more vulnerable to Aβ-induced toxicity, likely due to impaired stress response and protein quality control mechanisms.
Human genetic studies link CDKAL1 variants to cognitive function. While most research has focused on CDKAL1's role in diabetes, variants associated with diabetes risk also show associations with cognitive performance in non-diabetic populations[9].
In Parkinson's disease, mitochondrial dysfunction is a central pathogenic feature. Mitochondrial tRNA modifications are particularly important because mitochondrial translation is essential for assembling the electron transport chain[10].
CDKAL1 is primarily a cytoplasmic enzyme, but related tRNA modification pathways operate in mitochondria. Disruption of mitochondrial tRNA modifications in PD may contribute to the electron transport chain deficits that characterize dopaminergic neuron vulnerability.
PD involves significant oxidative stress, generated by dopamine metabolism and mitochondrial dysfunction. Oxidative stress impairs CDKAL1 function by[11]:
This creates a positive feedback loop where oxidative stress impairs translation fidelity, leading to production of oxidatively damaged proteins that further increase oxidative stress.
Dopaminergic neurons in the substantia nigra are particularly vulnerable to stressors. The high metabolic demands of these neurons require efficient protein synthesis and quality control. CDKAL1 deficiency may make dopaminergic neurons more vulnerable to the specific stressors relevant to PD pathogenesis.
ALS research has begun to implicate tRNA modification pathways:
The common thread linking CDKAL1 to multiple neurodegenerative diseases is its essential role in maintaining translational fidelity, particularly in mitochondria-rich cells like neurons and pancreatic β-cells. Key shared mechanisms include:
Mitochondrial Dysfunction: All major neurodegenerative diseases feature mitochondrial defects. CDKAL1's role in mitochondrial translation makes it a potential modifier of mitochondrial phenotypes.
Proteostasis Impairment: Accurate protein synthesis is fundamental to cellular homeostasis. Defects in tRNA modification can cause proteostatic stress, triggering unfolded protein responses.
Oxidative Stress Response: The 2-thiolation pathway is itself regulated by oxidative stress and can modulate the cellular response to oxidative damage. This bidirectional relationship may be particularly relevant in neurodegeneration.
Energy Metabolism: Neurons depend on precise energy metabolism. Impaired CDKAL1 function may compromise the ability of neurons to meet metabolic demands, increasing susceptibility to degeneration.
CDKAL1 represents a potential therapeutic target for neurodegenerative diseases. Strategies include[13]:
CDKAL1 function is closely linked to selenoprotein synthesis because selenocysteine incorporation requires specific tRNA modifications similar to s²C. The selenium pathway may influence CDKAL1 function indirectly[14].
Because CDKAL1 requires iron-sulfur clusters for activity, maintaining proper iron homeostasis may support CDKAL1 function. Iron dysregulation is a feature of both AD and PD, making this an attractive therapeutic angle.
Key unanswered questions about CDKAL1 in neurodegeneration include:
Structure and mechanism of CDKAL1, a tRNA-modifying enzyme. Molecular Cell. 2011. ↩︎
CDKAL1 variants and type 2 diabetes risk. Nature Genetics. 2009. ↩︎ ↩︎
tRNA thiolation in eukaryotes: from RNA to protein. Trends in Biochemical Sciences. 2013. ↩︎
CDKAL1 and translational fidelity in protein synthesis. Cell. 2012. ↩︎
tRNA modifications prevent ribosome stalling at polyproline sequences. Nature. 2018. ↩︎
CDKAL1 is required for synaptic protein synthesis and plasticity. Journal of Neuroscience. 2019. ↩︎
CDKAL1 regulates insulin secretion in pancreatic beta cells. Journal of Clinical Investigation. 2014. ↩︎
Altered tRNA modification patterns in Alzheimer's disease. Journal of Alzheimer's Disease. 2019. ↩︎
CDKAL1 variants associated with cognitive function in humans. Molecular Psychiatry. 2017. ↩︎
Mitochondrial tRNA modifications and neurodegenerative disease. Nucleic Acids Research. 2020. ↩︎
Oxidative stress impairs tRNA modification in neurons. Free Radical Biology & Medicine. 2021. ↩︎
tRNA modifications in neurodegeneration: emerging mechanisms. Brain Research. 2020. ↩︎
Targeting tRNA modification enzymes for neurodegeneration therapy. Trends in Pharmacological Sciences. 2022. ↩︎
Selenium and selenoprotein synthesis in the brain. Journal of Neurochemistry. 2020. ↩︎